256 related articles for article (PubMed ID: 16128833)
21. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation.
Sorsa T; Tjäderhane L; Konttinen YT; Lauhio A; Salo T; Lee HM; Golub LM; Brown DL; Mäntylä P
Ann Med; 2006; 38(5):306-21. PubMed ID: 16938801
[TBL] [Abstract][Full Text] [Related]
22. Protective effects of baicalin on ligature-induced periodontitis in rats.
Cai X; Li C; Du G; Cao Z
J Periodontal Res; 2008 Feb; 43(1):14-21. PubMed ID: 18230102
[TBL] [Abstract][Full Text] [Related]
23. Nonsteroidal anti-inflammatory drugs as adjuncts in the management of periodontal diseases and peri-implantitis.
Salvi GE; Williams RC; Offenbacher S
Curr Opin Periodontol; 1997; 4():51-8. PubMed ID: 9655021
[TBL] [Abstract][Full Text] [Related]
24. Experimental periodontitis in mice selected for maximal or minimal inflammatory reactions: increased inflammatory immune responsiveness drives increased alveolar bone loss without enhancing the control of periodontal infection.
Trombone AP; Ferreira SB; Raimundo FM; de Moura KC; Avila-Campos MJ; Silva JS; Campanelli AP; De Franco M; Garlet GP
J Periodontal Res; 2009 Aug; 44(4):443-51. PubMed ID: 18973535
[TBL] [Abstract][Full Text] [Related]
25. The effect of patient-centered plaque control and periodontal maintenance therapy on adverse outcomes of periodontitis.
Pastagia J; Nicoara P; Robertson PB
J Evid Based Dent Pract; 2006 Mar; 6(1):25-32. PubMed ID: 17138393
[TBL] [Abstract][Full Text] [Related]
26. The role of aspirin-triggered lipoxins in the mechanism of action of aspirin.
Gilroy DW
Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):203-10. PubMed ID: 15978791
[TBL] [Abstract][Full Text] [Related]
27. Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases.
Paquette DW; Williams RC
Periodontol 2000; 2000 Oct; 24():239-52. PubMed ID: 11276870
[TBL] [Abstract][Full Text] [Related]
28. Using host response modifiers in the treatment of periodontal disease. "The clinicians' view". [Interview].
Chichetti S; Bader H; Smith S; Barnett N; Barecki R; Testa D; Giannini J; Bass D; Vines I; DiSalvo P
Pract Proced Aesthet Dent; 2002; 14(9):suppl 12-5. PubMed ID: 12685429
[TBL] [Abstract][Full Text] [Related]
29. Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats.
Queiroz-Junior CM; Pacheco CM; Maltos KL; Caliari MV; Duarte ID; Francischi JN
J Periodontal Res; 2009 Apr; 44(2):153-60. PubMed ID: 19210344
[TBL] [Abstract][Full Text] [Related]
30. Cost-benefit, cost-effectiveness and cost-utility analyses of periodontitis prevention.
Braegger U
J Clin Periodontol; 2005; 32 Suppl 6():301-13. PubMed ID: 16128845
[TBL] [Abstract][Full Text] [Related]
31. The effects of the initial treatment phase and of adjunctive low-dose doxycycline therapy on clinical parameters and MMP-8, MMP-9, and TIMP-1 levels in the saliva and peripheral blood of patients with chronic periodontitis.
Górska R; Nedzi-Góra M
Arch Immunol Ther Exp (Warsz); 2006; 54(6):419-26. PubMed ID: 17122880
[TBL] [Abstract][Full Text] [Related]
32. The role of Periostat in the management of adult periodontitis: a critical assessment.
Greenstein G
Compend Contin Educ Dent; 1999 Jul; 20(7):664-8, 670, 672 passim. PubMed ID: 10650384
[TBL] [Abstract][Full Text] [Related]
33. Systemic Chemotherapeutic Agents as Adjunctive Periodontal Therapy: A Narrative Review and Suggested Clinical Recommendations.
Sheridan RA; Wang HL; Eber R; Oh TJ
J Int Acad Periodontol; 2015 Oct; 17(4):123-34. PubMed ID: 26727151
[TBL] [Abstract][Full Text] [Related]
34. Physiological mediators in nonsteroidal anti-inflammatory drugs (NSAIDs)-induced impairment of gastric mucosal defense and adaptation. Focus on nitric oxide and lipoxins.
Brzozowski T; Konturek PC; Pajdo R; Ptak-Belowska A; Kwiecien S; Pawlik M; Drozdowicz D; Sliwowski Z; Brzozowski B; Konturek SJ; Pawlik WW
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():89-102. PubMed ID: 18812631
[TBL] [Abstract][Full Text] [Related]
35. Periodontal and atherosclerosis-induced diseases.
Fardi A; Papadimitriou D
Int Angiol; 2007 Sep; 26(3):197-205. PubMed ID: 17622199
[TBL] [Abstract][Full Text] [Related]
36. Modulation of the host inflammatory response in periodontal disease management: exciting new directions.
Bhatavadekar NB; Williams RC
Int Dent J; 2009 Oct; 59(5):305-8. PubMed ID: 19998666
[TBL] [Abstract][Full Text] [Related]
37. Strategies for managing periodontal inflammation.
Schonfeld SE
J Calif Dent Assoc; 2010 Apr; 38(4):272-83. PubMed ID: 20509367
[TBL] [Abstract][Full Text] [Related]
38. Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors.
Garlet GP; Cardoso CR; Silva TA; Ferreira BR; Avila-Campos MJ; Cunha FQ; Silva JS
Oral Microbiol Immunol; 2006 Feb; 21(1):12-20. PubMed ID: 16390336
[TBL] [Abstract][Full Text] [Related]
39. Non-surgical treatment of peri-implant mucositis and peri-implantitis: a literature review.
Renvert S; Roos-Jansåker AM; Claffey N
J Clin Periodontol; 2008 Sep; 35(8 Suppl):305-15. PubMed ID: 18724858
[TBL] [Abstract][Full Text] [Related]
40. [The role of Matrix Metaloproteinases in the progression of periodontitis, and the use of specific inhibitors to these enzymes in the treatment of the periodontal disease].
Nasatzky E; Rubinstein Y; Goultschin J; Schwartz Z
Refuat Hapeh Vehashinayim (1993); 2003 Apr; 20(2):38-45, 81. PubMed ID: 12830492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
